Biocon’s Executive Chairperson Kiran Mazumdar-Shaw has mapped a five-year succession plan, naming her niece Claire Mazumdar as successor. The company expects a strong FY27 launch calendar, especially in the second half, driven by its “diabesity” franchise. It also reports significant debt reduction and will channel more operational cash flow toward further deleveraging as it targets a semaglutide push from FY28.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
